β-Cell Replacement Strategies: The Increasing Need for a "β-Cell Dogma"

Area of Science:

• Endocrinology and Metabolism
• Regenerative Medicine
• Cell Biology

Background:

• Type 1 diabetes (T1D) results from autoimmune destruction of pancreatic beta cells, leading to chronic hyperglycemia.
• Current insulin therapy improves glycemic control but does not restore normal life expectancy or quality of life.
• The increasing prevalence of diabetes necessitates the development of alternative therapeutic strategies.

Purpose of the Study:

• To review and analyze markers used for characterizing insulin-secreting cells generated from stem/precursor cells or via transdifferentiation.
• To identify discrepancies in the characterization of these engineered cells.
• To emphasize the need for standardized guidelines for cell characterization in T1D research.

Main Methods:

• Literature screening of studies published since 2011.
• Inventory and comparison of markers used to characterize *in vitro* differentiated and *in vivo* transdifferentiated insulin-producing cells.
• Analysis of discrepancies in cell characterization methodologies.

Main Results:

• Significant variations were observed in the markers employed to define insulin-producing cells across different studies.
• Discrepancies in characterization hinder the accurate assessment of cell functionality and identity.
• The field requires consistent criteria to evaluate the potential of engineered cells for T1D therapy.

Conclusions:

• Standardized guidelines are crucial for the reliable characterization of *in vitro* or *ex vivo* generated insulin-secreting cells.
• Establishing strict characterization protocols is essential before considering transplantation in type 1 diabetic patients.
• Harmonized approaches will facilitate the advancement of cell-based therapies for T1D.